This Stock Has Quadrupled in 5 Years. Can It Do It Again?
It's been a solid year for Krystal Biotech (NASDAQ: KRYS), a midcap company focusing on developing gene therapies, as it has easily outperformed the market this year. However, zooming out tells an even more impressive story: In the past five years, its shares have risen by 384% -- more than quadrupling in this period.
The company owes this performance to solid clinical and regulatory progress. But can it pull off something similar in the next half a decade? Let's find out.
Source Fool.com